Tinidazole for Recurrent Bacterial Vaginosis: A Pilot Study

Inclusion Criteria

• •1. Age 18-45 at time of enrollment.
• •2. Recurrent BV as defined by:
• •* 2 previously documented diagnoses of BV in the past 6 months or
• •* 3 previously documented diagnoses of BV in the past year
• •3. Non-pregnant, non-lactating.
• •4. Premenopausal.
• •5. Presence of bacterial vaginosis at the enrollment visit using Amsel Criteria (at least 3 of 4):
• •* Presence of homogenous vaginal discharge
• •* pH of vaginal secretions of \> 4.7
• •* Presence of a positive "whiff" test of the vaginal secretions upon mixing with 10% KOH
• •* Presence of \> 20% clue cells on saline microscopy
• •6. Willingness to undergo randomization to a possible placebo arm (for suppressive therapy).
• •7. Ability to undergo informed consent.
• •8. Willingness to refrain from use of any intravaginal products (including douching, contraceptive spermicides, creams, gels, foams).
• •9. Currently using an acceptable method of birth control (such as a hormonal method including oral contraceptives, Depo Provera, Ortho Evra, abstinence x 60 days, consistent condom use, surgically sterile, lesbian orientation).
• •10. Willing to refrain from alcohol consumption during use of study medication and three days following completion of medication (which includes the 10 day open label treatment and the entire 3 month suppressive phase of treatment).